DEXACORT
LOE ApproachingNDAINHALATIONAEROSOL, METERED
Approved
Sep 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DEXACORT is a metered-dose inhaled aerosol small-molecule corticosteroid approved in 1962 by UCB Pharma. The specific indication(s), mechanism of action, and pharmacologic class are not disclosed in available data. This is a legacy product with an established safety profile in inhalation therapy.
LOE Approaching
LOE-approaching status signals a contracting team focused on cost management and legacy market defense rather than growth investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DEXACORT as a commercial professional means managing a mature, declining brand with emphasis on margin protection, customer retention, and cost optimization rather than growth. Career advancement will be limited; this role is best suited for operational specialists or sales professionals seeking stability in a legacy portfolio.
Brand ManagerField Sales Representative
Worked on DEXACORT at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.